9L2 and ZCT Related Headlines
Go Back- Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact
- Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device
- Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device
- Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update
- Zero Candida Technologies to Present at the OTCQB Venture Virtual Investor Conference on August 7th
- Zero Candida Technologies Announces DTC Eligibility and to Present at OTCQB Venture Virtual Investor Conference on August 7th
9L2 and ZCT Related Press Releases
Go Back- Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact
- Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device
- Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device
- Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update
- Zero Candida Technologies to Present at the OTCQB Venture Virtual Investor Conference on August 7th
- Zero Candida Technologies Announces DTC Eligibility and to Present at OTCQB Venture Virtual Investor Conference on August 7th
